Part,  Chapter, Paragraph

 1   II,     6.  3.  2|   recently introduced conjugated vaccines. This suggests that vaccination
 2   II,     6.  3.  5|   bacterial infections for which vaccines are available for some of
 3   II,     6.  3.  5|       per 100 000 per year. Good vaccines are only available for one
 4   II,     6.  3.  5|       uptake remains poor.~ ~New vaccines have recently been, or soon
 5   II,     6.  3.  5|     question as to whether these vaccines should be included in vaccination
 6   II,     6.  3.  5|         in the uptake of certain vaccines, with important consequences
 7   II,     6.  3.  5|       the older ‘polysaccharide’ vaccines, a new generation of ‘conjugated’
 8   II,     6.  3.  5|       generation of ‘conjugated’ vaccines provide good protection
 9   II,     6.  3.  5|         young children. As these vaccines also protect against the
10   II,     6.  3.  5|        young children. Effective vaccines are available against invasive
11   II,     6.  3.  5|      live vaccine to inactivated vaccines in order to avoid vaccine
12   II,     6.  4.  3|   quickly; and~· availability of vaccines and anti-viral drugs.~ ~
13   II,     6.  4.  3| development of suitable pandemic vaccines, in consultation with the
14   II,     6.  4.  3|     availability and use of both vaccines and antiviral drugs.~ ~
15   II,     6.  4.  5|       alternative treatments and vaccines; b) support the development
16   II,     9.  2.  3|      with the development of new vaccines, the definition of what
17  III,    10.  3.  4|          no shortage of drugs or vaccines was reported. The provision
18   IV,    11.  4    |         cervical cancer~· Recent vaccines against Human Papilloma
19   IV,    12.  4    |      EMEA) on the development of vaccines, anti-virals and on antimicrobial